Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428–44.

Article  CAS  PubMed  Google Scholar 

Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat reviews Gastroenterol Hepatol. 2011;8(9):512–22. https://doi.org/10.1038/nrgastro.2011.131

Article  Google Scholar 

Ilyas SI, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–29. https://doi.org/10.1053/j.gastro.2013.10.013

Article  CAS  PubMed  PubMed Central  Google Scholar 

Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Klümpen HJ, et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022;76(5):1109–21. https://doi.org/10.1016/j.jhep.2021.12.010

Article  CAS  PubMed  Google Scholar 

Khan SA, Tavolari S, Brandi G, Cholangiocarcinoma. Epidemiology and risk factors. Liver international: official journal of the International Association for the Study of the Liver. 2019;39 Suppl 1:19–31. https://doi.org/10.1111/liv.14095

Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–84. https://doi.org/10.1016/S1470-2045(20)30109-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data. Liver international: official J Int Association Study Liver. 2023;43(8):1803–12. https://doi.org/10.1111/liv.15641

Article  CAS  Google Scholar 

Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694–704. https://doi.org/10.1016/S2468-1253(24)00095-5

Article  CAS  PubMed  Google Scholar 

Doherty B, Nambudiri VE, Palmer WC. Update on the Diagnosis and Treatment of Cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19(1):2. https://doi.org/10.1007/s11894-017-0542-4

Article  PubMed  Google Scholar 

Bridgewater J, Fletcher P, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. J Clin Oncol. 2022;40(18):2048–57. https://doi.org/10.1200/jco.21.02568

Article  PubMed  Google Scholar 

Brookes AJ. The essence of SNPs. Gene. 1999;234(2):177–86. https://doi.org/10.1016/s0378-1119(99)00219-x.

Article  CAS  PubMed  Google Scholar 

Shastry BS. SNPs: impact on gene function and phenotype. Methods Mol Biol. 2009;578:3–22. https://doi.org/10.1007/978-1-60327-411-1_1.

Article  CAS  PubMed  Google Scholar 

Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct Target Ther. 2021;6(1):254. https://doi.org/10.1038/s41392-021-00648-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rizvi S, Gores GJ. Molecular pathogenesis of cholangiocarcinoma. Dig Dis. 2014;32(5):564–9. https://doi.org/10.1159/000360502

Article  PubMed  PubMed Central  Google Scholar 

Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27–41. https://doi.org/10.1016/j.immuni.2019.06.025.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang G, Mantas A, Liu D, Al-Masri TM, Lueong SS, Siveke J, et al. The Prognostic Value of the XPC rs2228001 Single Nucleotide Polymorphism in Cholangiocarcinoma. Liver international: official J Int Association Study Liver. 2025;45(9):e70292. https://doi.org/10.1111/liv.70292.

Article  CAS  Google Scholar 

Lurje I, Czigany Z, Bednarsch J, Gaisa NT, Dahl E, Knuchel R, et al. Genetic Variant of CXCR1 (rs2234671) Associates with Clinical Outcome in Perihilar Cholangiocarcinoma. Liver cancer. 2022;11(2):162–73. https://doi.org/10.1159/000521613

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gurevich I, Zhang C, Francis N, Aneskievich BJ. TNIP1, a retinoic acid receptor corepressor and A20-binding inhibitor of NF-κB, distributes to both nuclear and cytoplasmic locations. J Histochem Cytochem. 2011;59(12):1101–12. https://doi.org/10.1369/0022155411427728.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang S, Fukushi M, Hashimoto S, Gao C, Huang L, Fukuyo Y, et al. A new ERK2 binding protein, Naf1, attenuates the EGF/ERK2 nuclear signaling. Biochem Biophys Res Commun. 2002;297(1):17–23. https://doi.org/10.1016/s0006-291x(02)02086-7.

Article  CAS  PubMed  Google Scholar 

Nanda SK, Venigalla RK, Ordureau A, Patterson-Kane JC, Powell DW, Toth R, et al. Polyubiquitin binding to ABIN1 is required to prevent autoimmunity. J Exp Med. 2011;208(6):1215–28. https://doi.org/10.1084/jem.20102177

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gurevich I, Aneskievich BJ. Liganded RARalpha and RARgamma interact with but are repressed by TNIP1. Biochem Biophys Res Commun. 2009;389(3):409–14. https://doi.org/10.1016/j.bbrc.2009.08.159

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tazi J, Bakkour N, Stamm S. Alternative splicing and disease. Biochim Biophys Acta. 2009;1792(1):14–26. https://doi.org/10.1016/j.bbadis.2008.09.017

Article  CAS  PubMed  Google Scholar 

Kawasaki A, Ito S, Furukawa H, Hayashi T, Goto D, Matsumoto I, et al. Association of TNFAIP3 interacting protein 1, TNIP1 with systemic lupus erythematosus in a Japanese population: a case-control association study. Arthritis Res Ther. 2010;12(5):R174. https://doi.org/10.1186/ar3134

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi Y, Zhang L, Bao Y, Wu P, Zhang X. Association of TNIP1 polymorphisms with hepatocellular carcinoma in a Northwest Chinese Han population. Med (Baltim). 2021;100(12):e24843. https://doi.org/10.1097/md.0000000000024843.

Article  CAS  Google Scholar 

Chen R, Zheng Y, Zhuo L, Wang S. The association between miR-423 rs6505162 polymorphism and cancer susceptibility: a systematic review and meta-analysis. Oncotarget. 2017;8(25):40204–13. https://doi.org/10.18632/oncotarget.16319.

Article  PubMed  PubMed Central  Google Scholar 

Pourmoshir N, Motalleb GH, Vallian S. hsa-miR-423 rs6505162 Is Associated with The Increased Risk of Breast Cancer in Isfahan Central Province of Iran. Cell J. 2020;22(Suppl 1):110–6. https://doi.org/10.22074/cellj.2020.7011

Article  PubMed  PubMed Central  Google Scholar 

Liu W, Zhang H, Ma J, Cheng Y, Luo W, Qian L, et al. Association of rs6505162 polymorphism in pre-miR-423 with cancer risk: A meta-analysis based on 5,891 cases and 7,622 controls. Int J Clin Exp Med. 2017;10:9754–63.

Google Scholar 

Cebrián A, Del Gómez T, Méndez-Vidal MJ, Gonzálvez ML, Lainez N, Castellano D, et al. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. Sci Rep. 2017;7:41371. https://doi.org/10.1038/srep41371

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou B, Zhang P, Wang Y, Shi S, Zhang K, Liao H, et al. Interleukin-17 gene polymorphisms are associated with bladder cancer in a chinese han population. Mol Carcinog. 2013;52(11):871–8.

Article  CAS